Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs
Mark Weiser(The University of Queensland), Julie Kreyenbuhl(University of Maryland, Baltimore), Eric P. Slade(University of Maryland, Baltimore), Li Fang(University of Maryland, Baltimore), John M. Davis(University of Illinois Chicago), Michael Davidson(Sheba Medical Center), Deborah R. Medoff(University of Maryland, Baltimore), Robert W. Buchanan(University of Maryland, Baltimore), Linda Levi(University of Maryland, Baltimore)
Cited by 23
Related Papers
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
|The Lancet|2013|2.5k
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
|The Lancet|2019|1.8k
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
|American Journal of Psychiatry|2016|1.1k
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
|The Lancet|2012|923
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
|Schizophrenia Bulletin|2009|915